Genelabs Technologies, Inc. Provides Update on Hepatitis C Drug Development with Collaboration Partners

June 23, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB) announced today that based on progress to date, its hepatitis C drug development and commercialization collaboration with Novartis is continuing to the next phase.

Twitter
LinkedIn
Facebook
Email
Print

Alliances

Novartis